Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for Perioperative Depressive Symptoms (PASSION II)
NCT04425473Phase 3Completed
- Sponsor
- Beijing Tiantan Hospital
- Start
- Feb 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of esketamine in major depressive disorder (MDD), sponsored by Beijing Tiantan Hospital. Started Feb 2021; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04425473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04425473.